Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Retained Earnings (2016 - 2025)

Kiora Pharmaceuticals' Retained Earnings history spans 11 years, with the latest figure at -$154.2 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 54556.16% year-over-year to -$154.2 million; the TTM value through Dec 2025 reached -$154.2 million, down 54556.16%, while the annual FY2025 figure was -$154.2 million, 54556.16% down from the prior year.
  • Retained Earnings reached -$154.2 million in Q4 2025 per KPRX's latest filing, down from -$147.7 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $1.2 million in Q1 2021 to a low of -$154.2 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$102.8 million, with a median of -$135.7 million recorded in 2024.
  • Peak YoY movement for Retained Earnings: surged 101.2% in 2021, then crashed 837935.15% in 2022.
  • A 5-year view of Retained Earnings shows it stood at -$86431.0 in 2021, then plummeted by 152582.49% to -$132.0 million in 2022, then fell by 11.38% to -$147.0 million in 2023, then surged by 99.81% to -$282159.0 in 2024, then tumbled by 54556.16% to -$154.2 million in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Retained Earnings are -$154.2 million (Q4 2025), -$147.7 million (Q3 2025), and -$147.7 million (Q2 2025).